

# ICH GWAS Monthly Newsletter

## December 15<sup>th</sup>, 2008

### In this issue:

1. ICH GWAS Newsletter
2. Sites and Investigators involved in the ICH GWAS
3. Consultants
4. Genotyping Process
5. Presentations from the Boston Meeting
6. Investigator Conference Call in January
7. Prioritization of samples based on phenotype quality
8. Update on DNA concentration and volume requirements for ICH GWAS samples
9. Update on Data Transferring Tools and Procedures

### 1. ICH GWAS Newsletter

This is the first issue of the monthly newsletter for the ICH GWAS Study Group. Our newsletter is will serve to keep investigators updated on all aspects of this project, including phenotyping, genotyping, data analysis, publications and logistics.

The newsletter will be sent out to participants on the 15<sup>th</sup> of each month (or nearest workday) as an email attachment from the Program Manager at the Coordinating Center.

If you want to add topics relevant to all investigators to the next newsletter, or you'd like to give general feedback to the Newsletter Design Team please contact [Lynelle Cortellini, M.Sc.](mailto:lcortellini@partners.org) ([lcortellini@partners.org](mailto:lcortellini@partners.org)).

### 2. Sites and Investigators involved in the ICH GWAS

New sites have joined the ICH GWAS study group in the last few months. This is an updated list (as of December 15<sup>th</sup> 2008) of all centers actively recruiting ICH cases and controls.

American sites recruiting as part of the GOCHA (Genetics of Cerebral Hemorrhage with Anticoagulation) Study:

#### Participating Site

Massachusetts General Hospital  
U. Michigan  
Mayo Clinic  
Beth Israel Deaconess Hospital  
U. Florida  
U. Washington  
U. Virginia  
Georgetown University

#### Investigators:

Jonathan Rosand, Steven M. Greenberg  
Devin Brown  
James Meschia  
Magdy Selim  
Scott Silliman  
David Tirschwell  
Brad Worrall  
Chelsea Kidwell

ISGC sites participating in the ICH GWAS Study:

**Participating Site**

Ludwig Maximilians University  
Jagiellonian University, Krakow  
Lund University Hospital  
Vall d'Hebron University Hospital  
IMIM-Hospital del Mar– Barcelona  
Graz University Hospital

**Investigators:**

Martin Dichgans  
Agnieszka Slowik  
Arne Lindgren, Bo Norrving  
Joan Montaner  
Jaume Roquer, Jordi Jimenez-Conde  
Reinhold Schmidt

**3. Consultants**

Massachusetts General Hospital/Broad Institute

Yuchiao Chang  
Mark Daly  
Shaun Purcell  
Daniel Singer  
Brian Gage  
Daniel Woo

Washington University  
U. Cincinnati

**4. Genotyping Process**

Genotyping for ICH GWAS samples is scheduled to begin in January – February 2009, following the timeline presented at the ICH GWAS Investigators Meeting (slides available on the ISGC website). This issue will be discussed in the next ICH GWAS Conference Call in January (topic no. 5).

**5. Presentations from the Boston meeting**

Presentations from the Boston ICH GWAS Investigators Meeting (November 5<sup>th</sup>, 2008) are now available on the ICH GWAS section of the ISGC website (<http://www.strokegenetics.org>).

Proposal Forms will soon also be available on the website for review. These forms will serve as the mechanism through which all investigators may propose analyses using the dataset.

In order to access the documents, please follow the instructions below:

- 1) Once at the website, log in on the left hand menu with "ISGCparticipant". This is both the username and password.
- 2) Once you are logged in, click on the "Members Area" tab at the top of the screen, then select the "ICH GWAS Project" from the left hand menu. The presentations are at the bottom of the page.
- 3) In order to view a presentation, you must enter the password "GOCHA" (all capital letters with a zero for the "O") in order to view it.

**6. Investigators Conference call in January**

In order to schedule our next conference call, we have arranged a Doodle survey directed to all participants in order to determine the best date and time for the group. Follow the link below and select your preferred date (please note: all times are US Eastern).

**Participation link:** <http://www.doodle.com/5wnzxd3nva6yt26g>

Participants will be able to vote until January 7<sup>th</sup>, 2009 at 12.00 pm (US Eastern Time)

***For further info on this topic please contact:***

Lynelle Cortellini, M.Sc. (MGH)  
lcortellini@partners.org

## **7. Prioritization of samples based on phenotype quality**

After reviewing and discussing data presented at the ICH GWAS Investigators Meeting in Boston we now propose a systematic scoring system to assess phenotype quality (completion) status for samples provided for the GWAS. This will in turn determine priority for genotyping.

### *GWAS inclusion requirements*

We will use a screening process in order to prioritize samples for genome-wide genotyping. Those samples that ultimately do not qualify for genome-wide analysis will then be used in replication studies.

For all samples, inclusion/exclusion Criteria must be confirmed and the following minimum data points must be available:

- Age
- Sex
- Race and Ethnicity
- Hypertension (Yes / No)
- Warfarin Status (at index)
- Aspirin / Antiplatelet Status (at index)
- CT scan performed at time of hospital admission for ICH

Depth of phenotyping and quality/availability of neuroimaging will then be used to select samples for genome-wide genotyping.

<b>Table – High relevance data points</b>
History of previous ICH
INR (Admission)
Quantification of Alcohol use
Quantification of Smoking exposure
First available GCS
Baseline, Discharge and Follow-up Modified Rankin / Glasgow Outcome Scale
First available Systolic / diastolic blood pressure recording
Cardiovascular risk factors (Diabetes, Coronary Artery Disease, CABG, Carotid artery disease...)
Prior TIA / Ischemic Stroke

### *Imaging availability determinants*

Imaging determinants are judged independently from the phenotypic data points.

Priority will be given to samples that are provided with:

- Follow-up CT
- MRI

### *Phenotype quality scoring system*

Phenotype data for samples will be graded according to the amount of data points available (expressed as percent of total data points required in case and control data forms).

Additional importance will be given to variables in **Table**, since they will be crucial as covariates and/or endpoints in the data analysis for the ICH GWAS

***For further info on this topic please contact:***

Alessandro Biffi, M.D. (MGH)  
abiffi@partners.org

## **8. Update on DNA concentration and volume requirements for ICH GWAS samples**

ICH GWAS samples sent to the Broad Institute for genotyping must meet the following criteria

- Concentration 50-80 ng/μl
- Volume 20 μl
- Total DNA 1 μg
- No amplified DNA samples.

Please note that a presentation from the Boston Investigators Meeting detailing sample requirements is available on the ICH GWAS section of the ISGC website.

***For further info on this topic please contact:***

Alessandro Biffi, M.D. (MGH)

[abiffi@partners.org](mailto:abiffi@partners.org)

## **9. Update on Data Transferring Tools and Procedures**

A presentation from the Boston ICH GWAS Investigators Meeting detailing sample and data transfer procedures is available on the ICH GWAS section of the ISGC website.

Please also note that further information on the Partners Secure File Transfer System (available for both phenotype and imaging data) can be obtained at <https://transfer.research.partners.org>.

***For further info on this topic please contact:***

Alessandro Biffi, M.D. (MGH)

[abiffi@partners.org](mailto:abiffi@partners.org)